Molecular biology of Kaposi's sarcoma-associated herpesvirus

被引:17
作者
Cotter, MA
Robertson, ES [1 ]
机构
[1] Univ Michigan, Sch Med, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2002年 / 7卷
关键词
KSHV; HHV-8; herpesvirus; Kaposi's sarcoma; primary effusion lymphoma; LANA; viral latency; review;
D O I
10.2741/cotter
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Over the past twenty odd years, kaposi's sarcoma has launched frombeing a rare pathological curiosity to a significant public health concern. This massive increase in incidence, concurrent with the aids epidemic, has sparked a tremendous amount of interest in uncovering the etiopathogenesis of this disease. Due to its striking association with hiv infection, researchers have focused on identifying a possible infectious agent as the cause of this disease. Such an agent, termed kaposi's sarcoma-associated herpes virus (kshv) was identified in 1994. In the following years, virologists have employed all of their molecular tools to characterize this new agent and its role in the pathogenesis of human disease. Indeed, these efforts have been quite fruitful. It is now known that kshv is a gammaherpesvirus, which like its relatives establishes a latent form of infection that appears to be a prerequisite for expression of a disease phenotype. The relevant disease states and the basic virology are discussed.
引用
收藏
页码:D358 / D375
页数:18
相关论文
共 213 条
[71]   Antibodies to Kaposi's sarcoma - Associated herpesvirus (human herpesvirus 8) in patients with multiple myeloma [J].
Gao, SJ ;
Alsina, M ;
Deng, JH ;
Harrison, CR ;
Montalvo, EA ;
Leach, CT ;
Roodman, GD ;
Jenson, HB .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (03) :846-849
[72]   KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway [J].
Gao, SJ ;
Boshoff, C ;
Jayachandra, S ;
Weiss, RA ;
Chang, Y ;
Moore, PS .
ONCOGENE, 1997, 15 (16) :1979-1985
[73]   KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma [J].
Gao, SJ ;
Kingsley, L ;
Li, M ;
Zheng, W ;
Parravicini, C ;
Ziegler, J ;
Newton, R ;
Rinaldo, CR ;
Saah, A ;
Phair, J ;
Detels, R ;
Chang, Y ;
Moore, PS .
NATURE MEDICINE, 1996, 2 (08) :925-928
[74]   Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma [J].
Gao, SJ ;
Kingsley, L ;
Hoover, DR ;
Spira, TJ ;
Rinaldo, CR ;
Saah, A ;
Phair, J ;
Detels, R ;
Parry, P ;
Chang, Y ;
Moore, PS .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (04) :233-241
[75]   Kaposi's sarcoma -: New treatment modalities [J].
Gascón, P ;
Schwartz, RA .
DERMATOLOGIC CLINICS, 2000, 18 (01) :169-+
[76]   KAPOSIS-SARCOMA IN ITALY BEFORE AND AFTER THE AIDS EPIDEMIC [J].
GEDDES, M ;
FRANCESCHI, S ;
BARCHIELLI, A ;
FALCINI, F ;
CARLI, S ;
COCCONI, G ;
CONTI, E ;
CROSIGNANI, P ;
GAFA, L ;
GIARELLI, L ;
VERCELLI, M ;
ZANETTI, R .
BRITISH JOURNAL OF CANCER, 1994, 69 (02) :333-336
[77]   BIRTHPLACE AND CLASSIC KAPOSIS-SARCOMA IN ITALY [J].
GEDDES, M ;
FRANCESCHI, S ;
BALZI, D ;
ARNIANI, S ;
GAFA, L ;
ZANETTI, R .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (13) :1015-1017
[78]   Chemokines activate Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture [J].
Gershengorn, MC ;
Geras-Raaka, E ;
Varma, A ;
Clark-Lewis, I .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (08) :1469-1472
[79]  
Gessain A, 1999, INT J CANCER, V81, P189, DOI 10.1002/(SICI)1097-0215(19990412)81:2&lt
[80]  
189::AID-IJC4&gt